- Home
- SBGI vs CTMX Comparison
SBGI vs CTMX Comparison
Compare SBGI & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SBGI | CTMX |
|---|---|---|
| Founded | 1986 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 941.1M | 977.1M |
| IPO Year | 2023 | 2015 |
Fundamental Metrics
Financial Performance| Metric | SBGI | CTMX |
|---|---|---|
| Price | $14.37 | $3.94 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 10 |
| Target Price | ★ $22.00 | $12.10 |
| AVG Volume (30 Days) | 434.3K | ★ 3.5M |
| Earning Date | 04-30-2026 | 05-08-2026 |
| Dividend Yield | ★ 6.56% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.28 | N/A |
| Revenue | ★ $3,169,000,000.00 | $76,201,000.00 |
| Revenue This Year | $12.37 | N/A |
| Revenue Next Year | N/A | $7.61 |
| P/E Ratio | $51.07 | ★ $22.58 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.89 | $1.72 |
| 52 Week High | $17.88 | $8.21 |
Technical Indicators
Market Signals| Indicator | SBGI | CTMX |
|---|---|---|
| Relative Strength Index (RSI) | 43.10 | 37.62 |
| Support Level | $12.67 | $3.83 |
| Resistance Level | $15.32 | $4.72 |
| Average True Range (ATR) | 0.66 | 0.25 |
| MACD | -0.22 | -0.03 |
| Stochastic Oscillator | 14.80 | 6.91 |
Price Performance
Historical ComparisonAbout SBGI Sinclair Inc.
Sinclair Inc. is the owner-operator of the second largest portfolio of television stations in the United States, with 185 full power stations in 86 markets, covering 40% of US households. Of the firm's roughly 600 channels, 150 are affiliated with the four national broadcasters—Fox, ABC, CBS, and NBC—with over 80 other channels aligned with The CW (Nexstar) and MyNetworkTV (Fox). Sinclair owns the Tennis Channel and stakes in Marquee Sports Network and YES Network, providing their premium sports content to pay-TV distributors.
About CTMX CytomX Therapeutics Inc.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.